Prevention and reversion of nonalcoholic steatohepatitis in OB/OB mice by S-nitroso-N-acetylcysteine treatment - PubMed (original) (raw)
Prevention and reversion of nonalcoholic steatohepatitis in OB/OB mice by S-nitroso-N-acetylcysteine treatment
Claudia P M S de Oliveira et al. J Am Coll Nutr. 2008 Apr.
Abstract
Objective: To evaluate the role oral administration of S-nitroso-N-acetylcysteine (SNAC), a NO donor drug, in the prevention and reversion of NASH in two different animal models.
Methods: NASH was induced in male ob/ob mice by methionine-choline deficient (MCD) and high-fat (H) diets. Two animal groups received or not SNAC orally for four weeks since the beginning of the treatment. Two other groups were submitted to MCD and H diets for 60 days receiving SNAC only from the 31(st) to the 60(th) day.
Results: SNAC administration inhibited the development of NASH in all groups, leading to a marked decrease in macro and microvacuolar steatosis and in hepatic lipid peroxidation in the MCD group. SNAC treatment reversed the development of NASH in animals treated for 60 days with MCD or H diets, which received SNAC only from the 31(st) to the 60(th) day.
Conclusions: Oral administration of SNAC markedly inhibited and reversed NASH induced by MCD and H diets in ob/ob mice.
Similar articles
- Hepatic gene expression profile associated with non-alcoholic steatohepatitis protection by S-nitroso-N-acetylcysteine in ob/ob mice.
de Oliveira CP, Stefano JT, de Lima VM, de Sá SV, Simplicio FI, de Mello ES, Corrêa-Giannella ML, Alves VA, Laurindo FR, de Oliveira MG, Giannella-Neto D, Carrilho FJ. de Oliveira CP, et al. J Hepatol. 2006 Nov;45(5):725-33. doi: 10.1016/j.jhep.2006.05.017. Epub 2006 Jul 5. J Hepatol. 2006. PMID: 16935387 - Modulation of hepatic microsomal triglyceride transfer protein (MTP) induced by S-nitroso-N-acetylcysteine in ob/ob mice.
Oliveira CP, Alves VA, Lima VM, Stefano JT, Debbas V, Sá SV, Wakamatsu A, Corrêa-Giannella ML, de Mello ES, Havaki S, Tiniakos DG, Marinos E, de Oliveira MG, Giannella-Neto D, Laurindo FR, Caldwell S, Carrilho FJ. Oliveira CP, et al. Biochem Pharmacol. 2007 Jul 15;74(2):290-7. doi: 10.1016/j.bcp.2007.04.013. Epub 2007 Apr 21. Biochem Pharmacol. 2007. PMID: 17524368 - Oral administration of S-nitroso-N-acetylcysteine prevents the onset of non alcoholic fatty liver disease in rats.
de Oliveira CP, Simplicio FI, de Lima VM, Yuahasi K, Lopasso FP, Alves VA, Abdalla DS, Carrilho FJ, Laurindo FR, de Oliveira MG. de Oliveira CP, et al. World J Gastroenterol. 2006 Mar 28;12(12):1905-11. doi: 10.3748/wjg.v12.i12.1905. World J Gastroenterol. 2006. PMID: 16609997 Free PMC article. - S-nitroso-N-acetylcysteine attenuates liver fibrosis in experimental nonalcoholic steatohepatitis.
Mazo DF, de Oliveira MG, Pereira IV, Cogliati B, Stefano JT, de Souza GF, Rabelo F, Lima FR, Ferreira Alves VA, Carrilho FJ, de Oliveira CP. Mazo DF, et al. Drug Des Devel Ther. 2013 Jun 28;7:553-63. doi: 10.2147/DDDT.S43930. Print 2013. Drug Des Devel Ther. 2013. PMID: 23843692 Free PMC article. - Current biochemical studies of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis suggest a new therapeutic approach.
Hookman P, Barkin JS. Hookman P, et al. Am J Gastroenterol. 2003 Sep;98(9):2093-7. doi: 10.1111/j.1572-0241.2003.07670.x. Am J Gastroenterol. 2003. PMID: 14499793 Review.
Cited by
- Oral administration of S-nitroso-L-glutathione (GSNO) provides anti-inflammatory and cytoprotective effects during ocular bacterial infections.
Das S, Ahmad Z, Singh S, Singh S, Wright RE 3rd, Giri S, Kumar A. Das S, et al. Cell Mol Life Sci. 2023 Sep 28;80(10):309. doi: 10.1007/s00018-023-04963-w. Cell Mol Life Sci. 2023. PMID: 37770649 Free PMC article. - Electron Therapy Attenuated Elevated Alanine Aminotransferase and Oxidative Stress Values in Type 2 Diabetes-Induced Nonalcoholic Steatohepatitis of Rats.
Enosawa S, Dozen M, Tada Y, Hirasawa K. Enosawa S, et al. Cell Med. 2013 Oct 23;6(1-2):63-73. doi: 10.3727/215517913X674225. eCollection 2013 Dec 30. Cell Med. 2013. PMID: 26858882 Free PMC article. - Herbal medicines for the treatment of nonalcoholic steatohepatitis: current scenario and future prospects.
Jadeja R, Devkar RV, Nammi S. Jadeja R, et al. Evid Based Complement Alternat Med. 2014;2014:648308. doi: 10.1155/2014/648308. Epub 2014 Jun 3. Evid Based Complement Alternat Med. 2014. PMID: 24987431 Free PMC article. Review. - Structural profiling of endogenous S-nitrosocysteine residues reveals unique features that accommodate diverse mechanisms for protein S-nitrosylation.
Doulias PT, Greene JL, Greco TM, Tenopoulou M, Seeholzer SH, Dunbrack RL, Ischiropoulos H. Doulias PT, et al. Proc Natl Acad Sci U S A. 2010 Sep 28;107(39):16958-63. doi: 10.1073/pnas.1008036107. Epub 2010 Sep 13. Proc Natl Acad Sci U S A. 2010. PMID: 20837516 Free PMC article. - Mitochondrial Dysfunction in the Transition from NASH to HCC.
Léveillé M, Estall JL. Léveillé M, et al. Metabolites. 2019 Oct 16;9(10):233. doi: 10.3390/metabo9100233. Metabolites. 2019. PMID: 31623280 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous